According to an update released by analysts at N 1 Singer the broker has now set a ‘Buy’ rating on shares of Ergomed (LON:ERGO) with a price target of 360.
N 1 Singer on Friday reiterated Ergomed’s analyst rating as ‘Buy’ with its price target of 360 highlighting a potential increase of 80% from Ergomed’s current price of 200.
Over the last twelve months Ergomed’s stock price has increased from 145 to 200, a change of 37.93%.
Ergomed has 40,031,000 shares in issue which have a share price of 200 giving Ergomed a market capitalisation of 80.06M GBp.
The company has a 50 day moving average of 202.82 and a 200 day moving average of 167.45. The 52 week high shares of Ergomed have reached is 216.88 whilst the 52 week low for the company’s shares is 117.
Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services. It is focused on oncology, neurology and immunology, and the development of orphan drugs. It has two businesses: Services Business and Co-Development Business. The Services Business is a clinical research business providing services to the pharmaceutical and biotechnology industry. The Co-Development Business is a portfolio of partnerships with pharmaceutical and biotechnology companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including out licensing milestones, as well as sales of the product. It provides clinical development, trial management and pharmacovigilance services to over 100 clients.